Vaxiion receives US patent for minicell-based therapeutics

The patent covers compositions of matter related to the antibody-based targeted delivery of biologically active compounds (including therapeutics) using Vaxiion’s minicell-delivery platform technology.

Vaxiion’s targeted therapeutic delivery platform is a biodegradable delivery technology based on recombinant nanoparticles, called minicells, derived from bacteria.

Vaxiion R&D executive vice president Michael Newman said that they have potent, broad-spectrum in vitro activity in various key cancer models and are expanding in vivo database with targeted minicells.

"Our data, combined with the issuance of this key patent in the US, positions Vaxiion well with respect to our development goals and business development efforts," Newman added.